Featured Research

from universities, journals, and other organizations

One step closer to countering deadly Nipah virus

Date:
June 25, 2014
Source:
University of Texas Medical Branch at Galveston
Summary:
A new breakthrough in countering the deadly Nipah virus has been announced by an interdisciplinary team of researchers. The human monoclonal antibody known as m102.4 is the first effective antiviral treatment for Nipah that has the potential for human therapeutic applications.

An interdisciplinary research team from the University of Texas Medical Branch at Galveston, the Uniformed Services University of the Health Sciences and three groups within the National Institutes of Health reports a new breakthrough in countering the deadly Nipah virus. The human monoclonal antibody known as m102.4 is the first effective antiviral treatment for Nipah that has the potential for human therapeutic applications.

Related Articles


Nipah and the closely related Hendra virus are highly infectious agents that emerged from Pteropid fruit bats in the 1990s, causing serious disease outbreaks in a variety of domestic animals and humans in Australia, Malaysia, Singapore, Bangladesh and India. Recent Nipah outbreaks have resulted in acute respiratory distress syndrome and encephalitis, person-to-person transmission and greater than 90 percent fatality rates among people. These properties make both Nipah and Hendra viruses a concern to human and livestock health.

Previous studies conducted by these researchers have found that the patented m102.4 antibody therapy could protect nonhuman primates from a deadly Hendra infection. In a paper appearing in Science Translational Medicine on June 25, the group describes the human monoclonal antibody therapy that protected nonhuman primates from disease at several time points after Nipah exposure, including the onset of clinical illness in this lethal disease.

"What makes this study unique is that we have achieved complete protection against death even in animals that received treatment five days after being infected with the Nipah virus when they otherwise would have succumbed within 8-10 days of infection," according to UTMB professor Thomas Geisbert, first author of the paper. "This recent success of the antibody therapy against Nipah virus disease in a nonhuman primate is a key step towards its development as a therapeutic for use in people."

Christopher Broder, USU professor and Geisbert's fellow senior author, stated that because of the new data and previous work with this antibody with Hendra virus experiments, "there was sufficient interest for the Queensland government in Australia to initiate a phase I clinical safety trial with m102.4 that is set to commence later this year."


Story Source:

The above story is based on materials provided by University of Texas Medical Branch at Galveston. Note: Materials may be edited for content and length.


Journal Reference:

  1. T. W. Geisbert, C. E. Mire, J. B. Geisbert, Y.-P. Chan, K. N. Agans, F. Feldmann, K. A. Fenton, Z. Zhu, D. S. Dimitrov, D. P. Scott, K. N. Bossart, H. Feldmann, C. C. Broder. Therapeutic Treatment of Nipah Virus Infection in Nonhuman Primates with a Neutralizing Human Monoclonal Antibody. Science Translational Medicine, 2014; 6 (242): 242ra82 DOI: 10.1126/scitranslmed.3008929

Cite This Page:

University of Texas Medical Branch at Galveston. "One step closer to countering deadly Nipah virus." ScienceDaily. ScienceDaily, 25 June 2014. <www.sciencedaily.com/releases/2014/06/140625141227.htm>.
University of Texas Medical Branch at Galveston. (2014, June 25). One step closer to countering deadly Nipah virus. ScienceDaily. Retrieved March 29, 2015 from www.sciencedaily.com/releases/2014/06/140625141227.htm
University of Texas Medical Branch at Galveston. "One step closer to countering deadly Nipah virus." ScienceDaily. www.sciencedaily.com/releases/2014/06/140625141227.htm (accessed March 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, March 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) — The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins